RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $60 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a $60 price target.
August 08, 2023 | 3:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharma's stock rating has been reiterated as Outperform by RBC Capital, with a maintained price target of $60.
The reiteration of an Outperform rating by a reputable analyst like Luca Issi from RBC Capital is a positive signal for Arrowhead Pharma. The maintained price target of $60 also indicates a positive outlook for the stock. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100